Reproductive Toxicity Study of CONF01, a New Antiarthritic Agent: Developmental Study in Rats
2005
Lee, J.S. (Chemon Inc., Yongin, Republic of Korea) | Hong, D.H. (Chemon Inc., Yongin, Republic of Korea) | Kim, K.H. (Chemon Inc., Yongin, Republic of Korea) | Zhang, H.S. (Chemon Inc., Yongin, Republic of Korea) | Gil, G.H. (Chemon Inc., Yongin, Republic of Korea) | Han, M.K. (Chemon Inc., Yongin, Republic of Korea) | Yang, H.J. (Chemon Inc., Yongin, Republic of Korea) | Bae, J.S. (Chemon Inc., Yongin, Republic of Korea) | Kim, N.D. (Chemon Inc., Yongin, Republic of Korea) | Song, S.W. (Chemon Inc., Yongin, Republic of Korea), E-mail: [email protected]
A developmental study of CONP01, a new antiarthritic agent, was conducted in Spra-gue-Dawley rats. Dosage of CONP01 0, 111, 333, and 1000 mg/kg/day were administered to dams orally from day 6 to day 16 of gestation. Two-third of dams per were subjected to caesarean section on day day 20 of pregnancy for examination of their fetuses, and the remaining one-third of dams per group were allowed to deliver naturally for postnatal examination of their offspring.
显示更多 [+] 显示较少 [-]